Table 2.
Adverse Eventsa.
| Liposomal Bupivacaine Group (N = 33) | Control Group (N = 26) | P | |
|---|---|---|---|
| Nausea | 13 (39.3) | 6 (23.0) | .263 |
| Vomiting | 6 (18.1) | 2 (7.6) | .445 |
| Constipation | 5 (15.1) | 5 (19.2) | .736 |
| Urinary retention | 4 (12.1) | 4 (15.3) | .721 |
| Hypotension | 6 (18.1) | 4 (15.3) | 1.000 |
| Arrhythmias | 0 (0) | 0 (0) | — |
| Pruritus | 4 (12.1) | 4 (15.3) | .721 |
| Headache | 3 (9.0) | 1 (3.8) | .623 |
| Acute mountain sickness | 1 (3.0) | 0 (0) | 1.00 |
| Acute respiratory distress | 0 (0) | 0 (0) | — |
| Desaturation | 1 (3.0) | 0 (0) | 1.00 |
| Pyrexia | 1 (3.0) | 0 (0) | 1.00 |
aValues presented as n (%).